- Home
- ALLT vs PLX Comparison
ALLT vs PLX Comparison
Compare ALLT & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLT
- PLX
- Stock Information
- Founded
- ALLT 1996
- PLX 1993
- Country
- ALLT Israel
- PLX Israel
- Employees
- ALLT N/A
- PLX N/A
- Industry
- ALLT Telecommunications Equipment
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALLT Telecommunications
- PLX Health Care
- Exchange
- ALLT Nasdaq
- PLX Nasdaq
- Market Cap
- ALLT 149.3M
- PLX 132.5M
- IPO Year
- ALLT 2006
- PLX 1998
- Fundamental
- Price
- ALLT $5.01
- PLX $1.76
- Analyst Decision
- ALLT Buy
- PLX
- Analyst Count
- ALLT 1
- PLX 0
- Target Price
- ALLT $13.00
- PLX N/A
- AVG Volume (30 Days)
- ALLT 649.2K
- PLX 382.4K
- Earning Date
- ALLT 02-13-2025
- PLX 11-14-2024
- Dividend Yield
- ALLT N/A
- PLX N/A
- EPS Growth
- ALLT N/A
- PLX N/A
- EPS
- ALLT N/A
- PLX N/A
- Revenue
- ALLT $91,631,000.00
- PLX $45,667,000.00
- Revenue This Year
- ALLT $0.41
- PLX N/A
- Revenue Next Year
- ALLT $8.84
- PLX $88.94
- P/E Ratio
- ALLT N/A
- PLX N/A
- Revenue Growth
- ALLT N/A
- PLX N/A
- 52 Week Low
- ALLT $1.45
- PLX $0.82
- 52 Week High
- ALLT $5.50
- PLX $1.90
- Technical
- Relative Strength Index (RSI)
- ALLT 62.41
- PLX 62.98
- Support Level
- ALLT $4.84
- PLX $1.60
- Resistance Level
- ALLT $5.05
- PLX $1.83
- Average True Range (ATR)
- ALLT 0.34
- PLX 0.08
- MACD
- ALLT -0.04
- PLX -0.02
- Stochastic Oscillator
- ALLT 48.42
- PLX 71.15
About ALLT Allot Ltd.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. It has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.